R21/MM Dosing, Presentations, and Preservatives

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

375

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Plasmodium Falciparum MalariaMalariaVaccine Reaction
Interventions
BIOLOGICAL

10μg R21/50μg Matrix-M

Adults and adolescents receiving the standard adult vaccine dose: 10μg R21/50μg Matrix-M (n=125)

BIOLOGICAL

5μg R21/50μg Matrix-M with adaptor preservative free

Adults and adolescents receiving a half of the standard adult vaccine dose: 5μg R21/50μg Matrix-M using two presentations: 10 dose vials with adaptor Preservative Free (n=125)

BIOLOGICAL

5μg R21/50μg Matrix-M with 2PE preservative

Adults and adolescents receiving a half of the standard adult vaccine dose: 5μg R21/50μg Matrix-M using two presentations: 10 dose vials with 2PE Preservative (n=125)

Trial Locations (2)

4641

Lama Upazila Health Complex, Lāma

4650

Alikadam Upazila Health Complex, Bāndarban

All Listed Sponsors
lead

University of Oxford

OTHER